上海醫藥(02607.HK)擬參與設立投資生物醫藥領域基金
格隆匯10月29日丨上海醫藥(02607.HK)公吿,於2024年10月29日,公司附屬公司上海生物醫藥前沿產業創新中心擬訂立合夥協議,內容有關參與設立標的基金,據此,上海生物醫藥前沿產業創新中心(作為有限合夥人)、國孚領航(作為有限合夥人)、奉賢生物科技(作為有限合夥人)、奉浦實業(作為有限合夥人)、生命信使(作為有限合夥人)、鄭效東(作為有限合夥人)、項金生(作為有限合夥人)、九旺投資(作為有限合夥人)、安永投資(作為有限合夥人)、曹紅光(作為有限合夥人)、上實資本(作為普通合夥人)及GP2(作為普通合夥人)將分別認購人民幣250百萬元、人民幣100百萬元、人民幣40百萬元、人民幣30百萬元、人民幣30百萬元、人民幣30百萬元、人民幣3百萬元、人民幣3百萬元、人民幣2百萬元、人民幣2百萬元、人民幣5百萬元及人民幣5百萬元的標的基金份額。
投資方向:生物醫藥領域具有國際領先水準的原創技術,其中包括精準醫療、生物技術、體外診斷和新興藥物篩選等細分賽道的境內外投資標的。
通過以上海生物醫藥前沿產業創新中心為橋樑參與訂立合夥協議設立標的基金,公司不僅可以獲取合理投資收益,還能夠吸引更多優秀的科研團隊和科創項目以及符合公司聚焦方向的優質項目。公司還可以通過影響項目進程與發展以推動投資孵化後的優質項目與公司達成研發與技術合作、產品權益轉讓以及產業合作等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.